ArticleEmerging infectious diseases2021
Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010-2018.
Article in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.
- Healthcare claims-based Lyme disease case-finding algorithms in the United States: A systematic literature review.PloS one · 2022Pooled it
- Trends in all-cause pneumonia and influenza hospitalization incidence by coding position - a study of US healthcare claims, 2014-2023.Pneumonia (Nathan Qld.) · 2026Article
- A Global, High-Resolution Index of Risk and Exposure of Humans to Ticks, Lyme Borreliosis, and Crimean-Congo Haemorrhagic Fever.Pathogens (Basel, Switzerland) · 2026Article
- The ecology of Lyme disease: Long-term data, surprises, and a synthesis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Mental health conditions among cancer survivors and individuals with and without comorbid chronic conditions: a retrospective claims analysis of patients with employee-sponsored insurance, 2012-2017.Journal of cancer survivorship : research and practice · 2026Article
- Using participatory epidemiology to understand differences in tick-borne disease perceptions from homeowners in the Ohio River valley.One health (Amsterdam, Netherlands) · 2026Article
- Predicting Lyme Disease: A One Health Approach.Pathogens (Basel, Switzerland) · 2026Article
- Bleeding and thrombotic outcomes with oral anticoagulants in patients with inflammatory bowel disease and venous thromboembolism.Blood advances · 2026Article
- Lyme Disease and Health Care Costs.JAMA network open · 2026Article
- Exploring data-driven algorithms to identify Lyme disease cases in electronic health records.PloS one · 2026Article
- Use of administrative data for evaluating trends in medically-attended Lyme disease, Manitoba, Canada, 2010-2021.PloS one · 2026Article
- Interlaboratory Concordance of a Multiplex ELISA for Lyme and Lyme-like Illness Using Australian Samples and Commercial Reference Panels: A Proof-of-Concept Study.Pathogens (Basel, Switzerland) · 2025Article
- Nonspecific Symptoms Attributable to Lyme Disease in High-Incidence Areas, United States, 2017-2021.Emerging infectious diseases · 2025Article
- Evasin and TSLPI Tick Salivary Antigen Subunit Vaccine Nanoparticles Induce Humoral and Cellular Immunity.ACS nanoscience Au · 2025Article
- Silent Carriers: The Role of Rodents in the Emergence of Zoonotic Bacterial Threats.Pathogens (Basel, Switzerland) · 2025Review
- Differences in Lyme Disease Diagnosis among Medicaid and Medicare Beneficiaries, United States, 2016-2021.Emerging infectious diseases · 2025Article
- Class and isotype of VlsE-specific antibody differentiates Lyme disease stage.Journal of clinical microbiology · 2025Article
- Extravasation of Borrelia burgdorferi Across the Blood-Brain Barrier is an Extremely Rare Event.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A high-resolution screen identifies a preexisting beta-lactam that specifically treats Lyme disease in mice.Science translational medicine · 2025Article
- The peptidoglycan ofScience translational medicine · 2025Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated MarketScan, a large commercial insurance claims database, for its potential use as a stable and consistent source of information on Lyme disease diagnoses in the United States. The age, sex, and geographic composition of the enrolled population during 2010-2018 remained proportionally stable, despite fluctuations in the number of enrollees. Annual incidence of Lyme disease diagnoses per 100,000 enrollees ranged from 49 to 88, ≈6-8 times higher than that observed for cases reported through notifiable disease surveillance. Age and sex distributions among Lyme disease diagnoses in MarketScan were similar to those of cases reported through surveillance, but proportionally more diagnoses occurred outside of peak summer months, among female enrollees, and outside high-incidence states. Misdiagnoses, particularly in low-incidence states, may account for some of the observed epidemiologic differences. Commercial claims provide a stable data source to monitor trends in Lyme disease diagnoses, but certain important characteristics warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.